Your browser doesn't support javascript.
loading
Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier.
Bonsignori, Mattia; Scott, Eric; Wiehe, Kevin; Easterhoff, David; Alam, S Munir; Hwang, Kwan-Ki; Cooper, Melissa; Xia, Shi-Mao; Zhang, Ruijun; Montefiori, David C; Henderson, Rory; Nie, Xiaoyan; Kelsoe, Garnett; Moody, M Anthony; Chen, Xuejun; Joyce, M Gordon; Kwong, Peter D; Connors, Mark; Mascola, John R; McGuire, Andrew T; Stamatatos, Leonidas; Medina-Ramírez, Max; Sanders, Rogier W; Saunders, Kevin O; Kepler, Thomas B; Haynes, Barton F.
Afiliação
  • Bonsignori M; Duke Human Vaccine Institute, Duke University, Durham, NC, USA; Department of Medicine, Duke University, Durham, NC, USA. Electronic address: mattia.bonsignori@duke.edu.
  • Scott E; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.
  • Wiehe K; Duke Human Vaccine Institute, Duke University, Durham, NC, USA; Department of Medicine, Duke University, Durham, NC, USA.
  • Easterhoff D; Duke Human Vaccine Institute, Duke University, Durham, NC, USA; Department of Medicine, Duke University, Durham, NC, USA.
  • Alam SM; Duke Human Vaccine Institute, Duke University, Durham, NC, USA; Department of Medicine, Duke University, Durham, NC, USA.
  • Hwang KK; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.
  • Cooper M; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.
  • Xia SM; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.
  • Zhang R; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.
  • Montefiori DC; Duke Human Vaccine Institute, Duke University, Durham, NC, USA; Department of Surgery, Duke University, Durham, NC, USA.
  • Henderson R; Duke Human Vaccine Institute, Duke University, Durham, NC, USA.
  • Nie X; Department of Immunology, Duke University, Durham, NC, USA.
  • Kelsoe G; Duke Human Vaccine Institute, Duke University, Durham, NC, USA; Department of Immunology, Duke University, Durham, NC, USA.
  • Moody MA; Duke Human Vaccine Institute, Duke University, Durham, NC, USA; Department of Pediatrics, Duke University, Durham, NC, USA.
  • Chen X; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Joyce MG; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Kwong PD; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Connors M; Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • McGuire AT; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA.
  • Stamatatos L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA.
  • Medina-Ramírez M; Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
  • Sanders RW; Department of Medical Microbiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY, USA.
  • Saunders KO; Duke Human Vaccine Institute, Duke University, Durham, NC, USA; Department of Surgery, Duke University, Durham, NC, USA.
  • Kepler TB; Department of Microbiology, Boston University School of Medicine, Boston, MA, USA.
  • Haynes BF; Duke Human Vaccine Institute, Duke University, Durham, NC, USA; Department of Medicine, Duke University, Durham, NC, USA; Department of Immunology, Duke University, Durham, NC, USA. Electronic address: barton.haynes@duke.edu.
Immunity ; 49(6): 1162-1174.e8, 2018 12 18.
Article em En | MEDLINE | ID: mdl-30552024
ABSTRACT
Elicitation of VRC01-class broadly neutralizing antibodies (bnAbs) is an appealing approach for a preventative HIV-1 vaccine. Despite extensive investigations, strategies to induce VRC01-class bnAbs and overcome the barrier posed by the envelope N276 glycan have not been successful. Here, we inferred a high-probability unmutated common ancestor (UCA) of the VRC01 lineage and reconstructed the stages of lineage maturation. Env immunogens designed on reverted VRC01-class bnAbs bound to VRC01 UCA with affinity sufficient to activate naive B cells. Early mutations defined maturation pathways toward limited or broad neutralization, suggesting that focusing the immune response is likely required to steer B cell maturation toward the development of neutralization breadth. Finally, VRC01 lineage bnAbs with long CDR H3s overcame the HIV-1 N276 glycan barrier without shortening their CDR L1, revealing a solution for broad neutralization in which the heavy chain, not CDR L1, is the determinant to accommodate the N276 glycan.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polissacarídeos / Infecções por HIV / HIV-1 / Vacinas contra a AIDS / Anticorpos Neutralizantes / Anticorpos Monoclonais Limite: Humans Idioma: En Revista: Immunity Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polissacarídeos / Infecções por HIV / HIV-1 / Vacinas contra a AIDS / Anticorpos Neutralizantes / Anticorpos Monoclonais Limite: Humans Idioma: En Revista: Immunity Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2018 Tipo de documento: Article